Quantitation of Oxylipins in Biological Samples, Focusing on Plasma, and Urine

O'Donnell, Valerie Bridget; Milne, Ginger L.; Nogueira, Marina Sayuri; Giera, Martin; Schebb, Nils Helge

doi:10.1002/9783527836512.ch12

Cited by 5 publications

(1 citation statement)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been widely reported within animal models that n-3 PUFA-derived SPMs could possibly play a role in the reduction of chronic inflammation through the hypothesis of resolving inflammation [48]. However, evidence of these molecules exerting a beneficial effect in humans has been lacking [8,49] and the detection of resolvins in plasma and their functional relevance in human biology is an active but controversial field of research [50][51][52][53].…”

Section: N-3 Pufa Cardiovascular Health Effectsmentioning

confidence: 99%

Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids

Caffrey,

Leamy,

O’Sullivan

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) remain the leading cause of death across the globe, hence, establishing strategies to counteract CVD are imperative to reduce mortality and the burden on health systems. Dietary modification is an effective primary prevention strategy against CVD. Research regarding dietary supplementation has become increasingly popular. This review focuses on the current in vivo, in vitro, and epidemiological studies associated with that of omega-3 polyunsaturated fatty acids (n-3 PUFAs) and polar lipids (PLs) and how they play a role against CVD. Furthermore, this review focuses on the results of several major clinical trials examining n-3 PUFAs regarding both primary and secondary prevention of CVD. Notably, we place a lens on the REDUCE-IT and STRENGTH trials. Finally, supplementation of PLs has recently been suggested as a potential alternative avenue for the reduction of CVD incidence versus neutral forms of n-3 PUFAs. However, the clinical evidence for this argument is currently rather limited. Therefore, we draw on the current literature to suggest future clinical trials for PL supplementation. We conclude that despite conflicting evidence, future human trials must be completed to confirm whether PL supplementation may be more effective than n-3 PUFA supplementation to reduce cardiovascular risk.

show abstract